Basiliximab

CLINICAL USE


Chimeric murine/human monoclonal anti CD25 antibody:

  • Prophylaxis of acute allograft rejection in combination with maintenance immunosuppression

    DOSE IN NORMAL RENAL FUNCTION

    20 mg 2 hours before transplant and 20 mg 4 days after transplant

    PHARMACOKINETICS

  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Approx 144 000
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
  • %Excreted unchanged in urine &nbsp &nbsp : No data
  • Volume of distribution (L/kg) &nbsp &nbsp &nbsp :4.5–12.7 litres
  • half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :4–10.4 days/Unchanged

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function

  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in normal renal function
  • HDF/high flux &nbsp :Unknown dialysability. Dose as in normal renal function
  • CAV/VVHD &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsCiclosporin: may alter ciclosporin requirementsTacrolimus: may alter tacrolimus requirements

    ADMINISTRATION

    Reconstition

    Reconstitute each vial with 5 mL water for injection then dilute to 50 mL or greater with sodium chloride 0.9% or glucose 5%

    Route

    IV infusion

    Rate of Administration

    20–30 minutes

    Comments

    OTHER INFORMATION

    cinIn vitro studies indicate that basiliximab binds only to activated lymphocytes
  • Basiliximab is detectable in serum for up to 3 months after 15–25 mg doses
  • Use with caution in patients who have previously had basiliximab due to increased risk of developing hypersensitivity reactions.